Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy

PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…

Read the full article here

Source: Journal of Clinical Oncology

Categories: Hem/Oncs, Latest Headlines

Tags: mmsm, nephroonc, onconeph

Tweets with this article

Mike Thompson, MD, PhD, FASCO

Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy [Jun 23, 2020] Bridoux et al. JCO @ASCO_pubs https://t.co/O9uteG4QXh #mmsm #onconeph #nephroonc n=186 NDMM w/ AKI not on HD https://t.co/GUFZxGDjUr

#mmMRD – Healthcare Social Media Analytics and Transcripts

What is #mmMRD? measurable residual disease, minimal residual disease, Multiple Myeloma. Healthcare Social Media Hashtag. Real-time Analytics.

Mike Thompson, MD, PhD, FASCO April 13, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…

Mike Thompson, MD, PhD, FASCO April 12, 2024

CTG Labs – NCBI

Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Mike Thompson, MD, PhD, FASCO April 12, 2024

Waging War on War Metaphors in Cancer and COVID-19

As oncologists, we are all too familiar with the use of war metaphors in clinical practice, which dates at least as far back as President…

Mike Thompson, MD, PhD, FASCO April 11, 2024

Introducing Hematology Tag Ontology

The Hematology Tag Ontology (HTO, Table 3) is presented here to help organize social media content of interest to hematologists and with some overlap with…

Mike Thompson, MD, PhD, FASCO April 10, 2024

Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities

Twitter use has increased among patients with cancer, advocates, and oncology professionals. Hashtags, a form of metadata, can be used to share content, organize health…

Mike Thompson, MD, PhD, FASCO April 10, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Mike Thompson, MD, PhD, FASCO April 9, 2024

Related Articles